Aspira Womans Health Inc (AWH)

[MWM]

That was a hard shake. Luckily I'm still holding all mine. I was waiting for $6 to return and then $4 showed up lol!

I want a retest of $6.75!

Those new warrants might have been sold on causing that dip maybe. Only 2 million had to be moved if they all sold. Luanch paid clear now!

[budgetthis]

Looking good........heading back up to the East Side.......

All Aboard ??

[1upandaway]

gapclose hope this goes up again today

[DTGoody]

Yes for sure!

[MWM]

Let's head back to that Premarket High!

[DTGoody]

Lord have Mercy! Congratulations!!!!

[DTGoody]

Going to open $7 LOL

[MWM]

1000 in various strikes...

[DTGoody]

Curious on how many $5 calls do you have?

[MWM]

$5.99!

[DTGoody]

Going to open $6 plus

[DTGoody]

I agree my friend! WOW!!

[MWM]

https://www.benzinga.com/general/biotech/20/06/16219829/the-daily-biotech-pulse-keytruda-setback-for-merck-denali-pulls-the-plug-on-neurological-asset

[MWM]

Just might be my Lucky day!

[budgetthis]

Up nicely in pre-market trading, Mike.

Congrats on finding this baby......so glad I followed you, yet again, to riches and glory......lol.

Perfect storm.

[MWM]

Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers
June 10, 2020 08:00 ET

AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence of COVID-19 antibodies. Our Laboratory has also completed validation of several additional oncology biomarkers. Both the COVID-19 antibody test and additional biomarkers will be used in an ASPIRA pelvic mass risk assessment pre-surgery workup.

ASPIRA Labs selected to validate the Roche Elecsys Anti-SARS-CoV-2 antibody test because it detects both IgG and IgM antibodies. Testing for IgG and IgM antibodies yields a specificity of 99.81% and a sensitivity of 100% (100% sensitivity when ≥14 days post PCR confirmation) 1 . The completed validation of COVID-19 antibody and additional pelvic mass risk assessment biomarkers will be offered commercially by the end of June in conjunction with our proprietary OVA1 ® plus test. The additional oncology biomarkers are CEA, CA19.9, LDH, Beta HCG, and AFP. These laboratory tests are essential in helping physicians identify less frequent ovarian tumor types as part of the pre-surgical workup.

“These additional offerings further establish ASPIRA Labs as a leader in pelvic mass assessment by providing physicians the ability to order tests for additional biomarkers. These offerings also help ensure physicians get access to all the testing they need to assess pelvic mass ovarian cancer risk especially in the current healthcare environment with COVID-19,” said Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc.

About Vermillion Inc.
Vermillion, Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ® plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPiRA GenetiX SM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans. Visit our website for more information about our products at www.vermillion.com .

[MWM]

$VRML Well we just hit the LOTTO!

[MWM]

New 8K Regulated Disclosure all warrants have been purchased at $1.80 raising $5 million! Impressive!

As previously reported, on February 17, 2017, Vermillion, Inc. (the “Company”) issued certain warrants (the “Warrants”) to purchase up to an aggregate of 2,810,338 shares of Company common stock, par value $0.001 per share (“Common Stock”), at an exercise price of $1.80 per share (the “Exercise Price”), pursuant to that certain Securities Purchase Agreement, dated February 13, 2017, by and among the Company and the investors listed on Schedule I thereto (collectively, the “Investors”). The Warrants were initially sold at a price of $0.125 per share of Common Stock underlying the Warrants.
?
On June 1, 2020, following the 20th consecutive trading day for which the closing price per share of Common Stock as reported on the Nasdaq Stock Market exceeded the Exercise Price, the Company sent a notice to the Investors accelerating the expiration date of the Warrants, in accordance with the terms thereof. Pursuant to the terms of the Warrants, any portion of the Warrants not exercised prior to such accelerated expiration date would become void and of no value. As of June 9, 2020, all of the Warrants had been exercised. The Company received $5,058,608 in aggregate proceeds from the exercise of the Warrants.
?
As of the date of this current report on Form 8-K, there are no outstanding Warrants or any other outstanding warrants for the purchase of Common Stock.

[Hypi]

They are letting them in the club! George Carlin use to say "its one big club and you & I aren't in it." Well with Cigna, FL St Medicare and now Russell 3000 membership we are on our way. Nice to belong.

[TAFAZI69]

Index russell...means ...more capital and investment found

[DTGoody]

Wow! There it is!!! Sweet!!!

[MWM]

Tomorrow might be fun! This might explain some of the move of late also...

[EdF]

That's great news. Should really help give VRML a sustained push.

[MWM]

$VRML Vermillion Set to Join Russell 3000® Index
June 09, 2020 16:34 ET
AUSTIN, Texas, June 09, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc.

(Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020, according to a preliminary list of additions posted on June 5, 2020.
Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“We are thrilled to join the Russell 3000 ® , which we believe will attract broader interest in Vermillion from institutional investors and investment funds,” said Valerie Palmieri, Chief Executive Officer of Vermillion, Inc. “We have made tremendous progress this year, both operationally and in year-over-year top line growth, even in the face of the challenges from the COVID-19 pandemic. We look forward to an easing of restrictions around the globe and a return to a more normal environment.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com

About Vermillion Inc.

Vermillion, Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ® plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans. Visit our website for more information about our products at www.vermillion.com .

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995 including statements regarding the anticipated addition of Vermillion common stock to the Russell 3000 Index and effects thereof. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in Vermillion’s business, including those described in the section entitled “Risk Factors” in Vermillion’s Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by the section entitled “Risk Factors” in Vermillion’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The events and circumstances reflected in Vermillion’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
?
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel [phone]
[e-mail]

[DTGoody]

Hopefully Tomorrow it gets a nice pop!

[MWM]

Buyers are attacking $4.50!

[DTGoody]

Volume is impressive today! I am probably going to regret selling my short term calls as this is looking like its heading to $5 or better on momentum.

[MWM]

Smart Move

[DTGoody]

Of course it's going to run like a bat out of hell now that I am out of my short-term calls. That is always how it goes for me! LOL So you may want to keep them short-term calls for a while longer? LOL

I just had too much money on those short term calls and it was nice getting my money back. I do feel something is definitely going to happen here, so I just followed the money on those longer term calls at $7.50. If something Big is announced this will blow right past $7.50 in a heartbeat! I only have about half of the contracts I had before, but its playing it more on the safe side with a lot more time.

[MWM]

Yeah, I need to do that as well...

[DTGoody]

I just swapped out my short-term calls for the long-term $7.50's. I followed the money here. Something is definitely going on here.

[MWM]

Incredible!

[DTGoody]

Broke through the final pivot point! Should get fun from here!

[DTGoody]

I would love for some major news to come out! VRML Chart looks Awesome! If we can Break through 4.25 that is the last level of resistance for the day.

[MWM]

VRML Something is happening. Fun to watch! The chart is a perfect Stairway!

[DTGoody]

This really could go nuts soon!

[MWM]

$VRML social media is as quiet as a mouse! It's Insane! Someone is loading their F-ing boat! Incredible!

[budgetthis]

Looking very strong today, guys.....

Rock on, Vermillion......

[DTGoody]

I agree something is coming.

[MWM]

VRML someone big is moving in here! Buyout must be coming or a major news event!

[MWM]

VRML is going a lot F-ing Higher! Just watch...

I added more $5 calls further out yesterday, don't want to miss this!

[MWM]

VRML that 500 block on the Jan $7.50 Calls yesterday was another buy. The Open interest has risen to 2500. Two 1000 share blocks week, now another 500 yesterday. About a $200K bet...

[DTGoody]

I agree very nice DD here Mike! Thank You!!

[EdF]

They need to amp up their IR efforts. Good things all around.

[MWM]

The Big One...

Vermillion Announces Cigna Preferred Contract Coverage for OVA1, Overa and Genetics Testing
March 27, 2020

[EdF]

Nice work Mikey, you painted a strong picture.

[DTGoody]

vrml looking really good!

[MWM]

Cigna let them in, who is next!

[Hypi]

Any product in the healthcare sector can only be successful if the big boys let them in and the way they keep you out is thru not approving insurance coverage. We have finally overcome that hurdle and I've followed this stock since the approval of OVA1. I lost a good chunk of change on these type of stocks because they weren't allowed a seat at the table.

VRML now has a legitimate seat at the table and since they have a better product there is no reason for doctors or insurers not to utilize OVA1. Coupled with their other solutions and this stock really has unlimited growth potential. IMO selling the place for $10 (a billion market cap) to a bigger player would make sense, though the company could easily be worth billions of dollars down the road.

[MWM]